The Non-Malignant Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCAT 2024 | Long-term updates from the REACH trial of hydroxyurea in pediatric patients with SCD in SSA
Leon Tshilolo, MD, PhD, Centre Hospitalier Monkole, Kinshasa, DR Congo, discusses the long-term results of the REACH trial (NCT01966731), the first trial investigating the use of hydroxyurea in pediatric patients with sickle cell disease (SCD) in sub-Saharan Africa (SSA). Prof. Tshilolo highlights the positive findings, both in terms of clinical outcomes and the social impacts of the treatment. This interview took place at the 19th Annual Scientific Conference of the Academy for Sickle Cell and Thalassaemia (ASCAT 2024) in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Novo Nordisk, Pfizer.
